Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has received Category III Current ...
A flurry of such tests that look for multiple cancers with a prick are in various stages of development. The one that is ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...
For more information about Candel, visit: www.candeltx.com.
People in NEPA get colorectal cancer more than the national average. An ensemble of doctors and pro musicians will sing about ...
March is Colorectal Cancer Awareness Month. See how American Cancer Society researchers are helping put an end to this disease. American Cancer Society (ACS) researchers study the most effective ways ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results